213 results about "Carcinomatoses" patented technology

The present invention relates to a device for simultaneously treating a tumor or cancerous growth with both hyperthermia and X-ray radiation using brachytherapy. The device includes a needle-like introducer serving as a microwave antenna. Microwaves are emitted from the introducer to increase the temperature of cancerous body tissue. The introducer is an inner conductor of a coaxial cable. The introducer contains a hollow core which houses an X-ray emitter. The X-ray emitter is connected to a high voltage miniature cable which extends from the X-ray emitter to a high voltage power source. The X-ray emitter emits ionizing radiation to irradiate cancerous tissue. A cooling system is included to control the temperature of the introducer. Temperature sensors placed around the periphery of the tumor monitor the temperature of the treated tissue.

Provided are reagents and methods for administering an attenuated bacterium and a binding compound for treating a cancerous or infectious condition, where the binding compound comprises an antibody or an antigen binding site derived from an antibody.

The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.

The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I):wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

The present invention is flurbiprofen ester injection as antiphlogistic and analgetic medicine and its preparation process. Main medicine and supplementary material including solvent, emulsifier, isotonic agent, buffering agent and pH regulator are mixed to compound the injection. Compared with available oral flurbiprofen preparation, the flurbiprofen ester injection has even high curative effect, even fast action, long lasting effect and less stomach mucous membrane damage and other negative effect. The present invention is used in treating chronic rheumarthritis, etc and is especially suitable for relieve post-operational pain and pain caused by cancer, and it has high effect and no addiction.

The invention relates to a method for the determination of a cancer diagnostic / therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein / peptide biomarkers and drug-targets based on the measurement of protein / peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein / peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein / peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein / peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein / peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and / or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein / peptide biomarkers those which show a mass-spectrometrically measurable and / or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein / peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself.

The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies. Also provided is a method of method of treating a cancerous or pre-cancerous condition of the respiratory tract in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity.